(FLGT) Fulgent Genetics - Ratings and Ratios
Molecular Diagnostics,Genetic Testing,Anatomic Pathology,Oncology Assays,Therapeutic Development
FLGT EPS (Earnings per Share)
FLGT Revenue
Description: FLGT Fulgent Genetics October 22, 2025
Fulgent Genetics, Inc. (NASDAQ: FLGT) delivers a broad portfolio of clinical diagnostic services-including molecular and genetic testing, anatomic pathology across multiple subspecialties, and oncology-focused assays-while also offering sequencer services for hereditary cancer and reproductive health.
In parallel, the company is advancing a nano-encapsulation and targeted-therapy platform aimed at improving the therapeutic window and pharmacokinetics of both novel and repurposed oncology drugs, positioning it as a hybrid diagnostics-therapeutics player.
Founded in 2011 and rebranded from Fulgent Diagnostics in 2016, the firm operates a proprietary “picture genetics” platform that combines gene probes, adaptive-learning algorithms, and a custom laboratory information management system to generate actionable health-marker insights for a diverse client base that includes insurers, hospitals, government agencies, and large employers.
Key recent metrics: FY 2023 revenue reached $322 million, up 18 % year-over-year, driven by a 24 % increase in molecular test volume; cash and cash equivalents stood at $115 million at year-end, providing runway for R&D expansion; and the company’s gross margin improved to 62 % as it scales high-margin sequencing services.
Sector drivers that could amplify FLGT’s growth include the accelerating adoption of precision-medicine testing (projected CAGR ≈ 12 % through 2028), expanding payer coverage for hereditary cancer panels, and a broader industry shift toward integrated diagnostic-therapeutic solutions that streamline patient pathways.
For a deeper, data-rich assessment of how these dynamics translate into valuation upside, you may find it worthwhile to explore the FLGT analysis on ValueRay.
FLGT Stock Overview
| Market Cap in USD | 717m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2016-09-29 |
FLGT Stock Ratings
| Growth Rating | -17.3% |
| Fundamental | 25.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -11.7% |
| Analyst Rating | 3.33 of 5 |
FLGT Dividends
Currently no dividends paidFLGT Growth Ratios
| Growth Correlation 3m | 90.1% |
| Growth Correlation 12m | 64.5% |
| Growth Correlation 5y | -92.4% |
| CAGR 5y | -13.46% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.22 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.36 |
| Sharpe Ratio 12m | -0.72 |
| Alpha | -4.88 |
| Beta | 0.976 |
| Volatility | 38.55% |
| Current Volume | 298.3k |
| Average Volume 20d | 191.6k |
| Stop Loss | 22.3 (-3.5%) |
| Signal | 1.13 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-51.0m TTM) > 0 and > 6% of Revenue (6% = 18.2m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -5.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 117.9% (prev 111.2%; Δ 6.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -25.1m > Net Income -51.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (30.8m) change vs 12m ago 2.44% (target <= -2.0% for YES) |
| Gross Margin 40.04% (prev 37.06%; Δ 2.98pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 24.94% (prev 23.59%; Δ 1.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -266.1 (EBITDA TTM -43.8m / Interest Expense TTM 255.0k) >= 6 (WARN >= 3) |
Altman Z'' 9.84
| (A) 0.30 = (Total Current Assets 428.7m - Total Current Liabilities 71.3m) / Total Assets 1.20b |
| (B) 0.47 = Retained Earnings (Balance) 560.0m / Total Assets 1.20b |
| (C) -0.06 = EBIT TTM -67.9m / Avg Total Assets 1.22b |
| (D) 6.42 = Book Value of Equity 566.0m / Total Liabilities 88.2m |
| Total Rating: 9.84 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.08
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -13.89% = -5.0 |
| 3. FCF Margin -19.77% = -7.41 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 1.84 = 0.32 |
| 6. ROIC - WACC (= -14.88)% = -12.50 |
| 7. RoE -4.52% = -0.75 |
| 8. Rev. Trend -13.11% = -0.98 |
| 9. EPS Trend 58.35% = 2.92 |
What is the price of FLGT shares?
Over the past week, the price has changed by -0.86%, over one month by +1.45%, over three months by +25.87% and over the past year by +7.19%.
Is Fulgent Genetics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FLGT is around 20.62 USD . This means that FLGT is currently overvalued and has a potential downside of -10.77%.
Is FLGT a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the FLGT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.3 | 9.6% |
| Analysts Target Price | 25.3 | 9.6% |
| ValueRay Target Price | 23.2 | 0.4% |
FLGT Fundamental Data Overview October 30, 2025
P/E Forward = 7.9365
P/S = 2.3652
P/B = 0.6278
P/EG = 1.32
Beta = 0.976
Revenue TTM = 303.2m USD
EBIT TTM = -67.9m USD
EBITDA TTM = -43.8m USD
Long Term Debt = 1.96m USD (from longTermDebt, last quarter)
Short Term Debt = 1.66m USD (from shortTermDebt, last quarter)
Debt = 7.39m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -80.5m USD (from netDebt column, last quarter)
Enterprise Value = 431.6m USD (717.2m + Debt 7.39m - CCE 292.9m)
Interest Coverage Ratio = -266.1 (Ebit TTM -67.9m / Interest Expense TTM 255.0k)
FCF Yield = -13.89% (FCF TTM -60.0m / Enterprise Value 431.6m)
FCF Margin = -19.77% (FCF TTM -60.0m / Revenue TTM 303.2m)
Net Margin = -16.83% (Net Income TTM -51.0m / Revenue TTM 303.2m)
Gross Margin = 40.04% ((Revenue TTM 303.2m - Cost of Revenue TTM 181.8m) / Revenue TTM)
Gross Margin QoQ = 42.10% (prev 38.59%)
Tobins Q-Ratio = 0.36 (Enterprise Value 431.6m / Total Assets 1.20b)
Interest Expense / Debt = 0.23% (Interest Expense 17.0k / Debt 7.39m)
Taxrate = 10.52% (-2.26m / -21.5m)
NOPAT = -60.7m (EBIT -67.9m * (1 - 10.52%)) [loss with tax shield]
Current Ratio = 6.01 (Total Current Assets 428.7m / Total Current Liabilities 71.3m)
Debt / Equity = 0.01 (Debt 7.39m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 1.84 (negative EBITDA) (Net Debt -80.5m / EBITDA -43.8m)
Debt / FCF = 1.34 (negative FCF - burning cash) (Net Debt -80.5m / FCF TTM -60.0m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.25% (Net Income -51.0m / Total Assets 1.20b)
RoE = -4.52% (Net Income TTM -51.0m / Total Stockholder Equity 1.13b)
RoCE = -6.00% (EBIT -67.9m / Capital Employed (Equity 1.13b + L.T.Debt 1.96m))
RoIC = -5.37% (negative operating profit) (NOPAT -60.7m / Invested Capital 1.13b)
WACC = 9.51% (E(717.2m)/V(724.6m) * Re(9.61%) + D(7.39m)/V(724.6m) * Rd(0.23%) * (1-Tc(0.11)))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.77%
Fair Price DCF = unknown (Cash Flow -60.0m)
EPS Correlation: 58.35 | EPS CAGR: 291.8% | SUE: 1.15 | # QB: 6
Revenue Correlation: -13.11 | Revenue CAGR: -8.88% | SUE: 0.79 | # QB: 0
Additional Sources for FLGT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle